Chapter 25: Antidysrhythmic Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today we're plugging directly into the heart's electrical system.

We want to understand what happens when that rhythm breaks down.

And more importantly, the critical pharmacology we rely on to restore order,

antidisrhythmic drugs.

Exactly.

This is your essential shortcut really to mastering how these high alert medications function.

And it's a really critical deep dive for you because these cardiac rhythm disturbances, we usually prefer the term dysrhythmias over arrhythmias.

They're pretty common.

You see them a lot after heart attacks, right?

Oh, definitely.

Following myocardial infarction during cardiac surgery, or sometimes just as a result of chronic coronary artery disease,

ultimately though, they all stem from the same core issue,

abnormally functioning cardiac cells and their electrical impulses.

So our mission today is to kind of build a roadmap, starting from the basic electrophysiology and going all the way to patient safety.

Right.

We're going to use the detailed von Williams classification system.

It helps instantly connect the drugs mechanism to its risk profile.

So by the end, you won't just know what the drug classes are, why they do what they do,

and most importantly, how to apply the nursing process safely.

Okay.

So to anchor this whole discussion, we need a quick look at the cardiac cell when it's just resting.

Every cell has what's called a resting membrane potential.

That's maintained by that sodium potassium pump, isn't it?

The AT pace pump.

Spot on.

It keeps the inside of the cell negative compared to the outside.

Then when electrical impulse hits it, bang, that charge changes dramatically.

It fires off what we call the action potential.

Okay.

Let's unpack this action potential then understanding these phases is really the key to getting where these drugs actually work.

So there are five phases, zero through four.

Let's start with phase zero.

That's the big up stroke, right?

Rapid depolarization and rapid is the word phase zero happens because the cell membrane suddenly opens up these fast channels and sodium ions just flood in a huge rush of ions.

Exactly.

An explosive, very rapid movement.

And that's what drives the contraction in what we call the fast tissues, primarily the Purkinje fibers and the ventricles.

Okay.

So if phase zero is so heavily sodium dependent,

does that mean a class I drug, a sodium channel blocker would hit those fast contracting tissues like the ventricles really hard and fast?

Precisely.

That's the whole basis for class I drugs.

Now contrast that with phase two.

That's the plateau phase.

Right.

Things kind of level off for a bit.

Yeah.

And that's because calcium ions start moving in through what we call slow channels.

This influx of positive calcium roughly balances the potassium ions that are flowing out and this balancing act is calcium influx.

That's what lengthens the action potential gives the heart time to fill.

Exactly.

It extends the duration, which is crucial.

And understanding these slow calcium channels is key for the other main type of cardiac tissue.

The SA and AV nodes.

You got it.

The SA node, our natural pacemaker and the AV node, the gatekeeper, they're primarily slow channel tissue.

Their firing relies heavily on that calcium influx.

So drugs that block calcium channels, the class I drugs, they're going to mainly affect the nodes, slowing the heart rate and conduction there.

Exactly.

They significantly impact nodal conduction rates, slowing the heart rate, slowing conduction through the AV node, but they don't have a huge effect on the actual speed of ventricular contraction itself because that's more sodium driven.

Okay.

Then phase three is where repolarization finishes up, the cell resets.

Right.

Getting back towards negative.

And then by phase four, the sodium potassium pump has done its job, restored that resting membrane potential and the cell is ready for the next beat.

Got it.

We also need to quickly touch on two key terms the drugs often manipulate.

First one is automaticity.

Ah, yes.

That's the cell's inherent ability to just depolarize on its own, spontaneously generate an impulse, which is normal.

And they say, no, that's its job.

Right.

That's our pacemaker.

But if other cells start doing that outside the normal conduction pathway, we call those ectopic foci.

And those are often the culprits behind dangerous rhythms in the second term, the refractory period, right after a cell fires, it enters the effective refractory period, the ERP.

During this time, it absolutely cannot be re stimulated no matter how strong the incoming signal is.

It's like a mandatory rest period.

Precisely.

And many anti -dysrhythmics, particularly class one and class three, work by actually extending that ERP, making that rest period longer.

Which protects the cell from firing too early or chaotically.

Exactly.

It prevents those premature disorganized beats.

And we treat these dysrhythmias because, well, they can be incredibly dangerous.

Thinking about atrial fibrillation, AF, that disorganized quivering in the atria.

Right.

The blood just pools, doesn't move efficiently, which massively increases the risk of clots forming and causing a stroke.

Or on the ventricular side, you have ventricular fibrillation, VF.

That's legal, isn't it?

Instantly fatal, if not corrected immediately.

It's just chaotic electrical activity, no effect of pumping.

And VF is often preceded by something called torsades to point.

That twisting of the points rhythm.

Yeah.

It's a specific type of rapid ventricular tachycardia.

And it's often triggered when the QT interval on the ECG gets too long.

That's a huge red flag we watch for with many of these drugs.

Okay.

So to manage this whole spectrum of electrical chaos,

we use the Vaughan Williams classification system.

It's the most common framework, really, our clinical roadmap.

It categorizes these drugs based purely on where they interfere with that action potential cycle we just talked about and which specific ion channel they target.

Makes sense.

So let's break down those four main classes, starting with class one.

Class one, these are the sodium channel blockers.

They target phase zero, that rapid up stroke, sometimes called membrane stabilizing agents.

And they primarily hit the fast tissues, ventricles, Burkina Fibers.

Spot on.

And they're subdivided further into IA, EB, and IFEC based on sort of subtle differences in how they affect the overall length of the action potential, the repolarization time.

Okay, then class two drugs.

Those are beta blockers, think metaprolol, atenolol.

They're hugely cardioprotective.

How do they work electrically?

They work by blocking the effects of the sympathetic nervous system on the heart.

Electrically, their main action is depressing phase four depolarization, especially in the SA and AV nodes, so they slow things down.

Makes sense.

Class three, you called these the heavy artillery earlier.

Ha, yes, often they are.

Amiodarone is the big one here.

These drugs work mainly by prolonging repolarization, phase three.

They stretch out the action potential duration.

Which means they significantly extend that effective refractory period, the ERP.

Exactly.

They make the cell less excitable for a longer time.

Very useful for stubborn, dangerous rhythms.

And finally, class four are calcium channel blockers, verapamil, diltiazum.

As we discussed, they block those slow calcium channels.

So they primarily target the slow channel tissues, the SA and AV nodes.

Right.

Depressing phase four depolarization there, slowing the heart rate and AV conduction.

And then, of course, there are a few other or unclassified agents, like adenosine, which has a very unique mechanism outside this system.

Okay, that framework is helpful.

Now let's dive into the specifics for each class, because the safety details, the clinical pearls,

that's where this really matters in practice.

Absolutely.

Let's start with class Ia, quinidine and prokainamide.

They block sodium channels, like all classes.

Right.

But you said they also delay repolarization, making the action potential longer.

Correct.

Now, the key clinical watchouts.

With prokainamide, you need to be aware of a pretty significant risk, up to 30 % on long -term therapy, of developing a drug -induced lupus syndrome, systemic lupus, erythematosus -like syndrome.

Wow, 30 % is high.

And quinidine.

Quinidine has its own issues.

Risk of something called synkinism.

It sounds old, but the symptoms are real.

Tinnitus, ringing in the ears, blurred vision, significant GI upset.

Okay.

But critically, quinidine carries a black box warning.

It's associated with increased mortality, and it can provoke that dangerous torsades de pointe rhythm, that QT prolongation risk is serious.

Got it.

Moving to class E, we have lidocaine.

It also blocks sodium channels, but differently, right?

Yeah.

It accelerates repolarization.

Yes, exactly.

It shortens the action potential duration slightly.

This difference means it's primarily used for ventricular dysrhythmias only.

One way it helps is by raising the threshold for ventricular fibrillation.

It makes VF less likely to occur.

And its pharmacology is interesting.

It has to be given IV.

Must be IV.

It undergoes such extensive metabolism on its first pass through the liver that taking it orally just doesn't work.

The drug is gone before it reaches the bloodstream.

And that liver metabolism has implications for dosing.

Huge implications.

If you have a

you must reduce the standard lidocaine dosage, usually by about 50 % right off the bat.

Otherwise, toxicity is almost guaranteed.

Okay.

Now for the really critical safety point with lidocaine,

the labeling.

Yes, this is non -negotiable.

You have to be incredibly meticulous.

Lidocaine vials are specifically labeled either A4R cardiac use or not for cardiac use.

Why the distinction?

Because lidocaine is also used as a local anesthetic, often combined with epinephrine.

Epinephrine is a potent vasoconstrictor.

It helps keep the anesthetic localized and reduces bleeding.

And that combination.

That combination of lidocaine with epinephrine must never, absolutely never, be given intravenously to treat a cardiac dysrhythmia.

Injecting epinephrine AV like that can be fatal.

It's only for local topical use.

Wow.

Okay.

So check the vial.

Always.

What does lidocaine toxicity look like if it does occur?

Primarily central nervous system effects.

CNS toxicity.

Things like muscle twitching, tremors, confusion, drowsiness, and in severe cases, convulsions or respiratory arrest.

Okay.

Let's shift to class Ike.

Fleconide and propofenone.

Strong sodium channel blockers.

Very potent sodium channel blockade.

But they have relatively little effect on how long repolarization takes.

They're very effective at suppressing things like premature ventricular contractions, PVCs.

But there's a history here, isn't there, with fleconide?

There is.

A sobering one.

Fleconide's use was sharply curtailed years ago because of the KST study, the Cardiac Arrhythmia Suppression Trial.

It found that in post -MI patients, fleconide actually increased the rate of non -fatal cardiac arrest and overall mortality, even though it suppressed PVCs.

That's paradoxical.

Treating one problem caused a worse one.

Exactly.

Now, clinical thinking has evolved a bit, and it is considered first line for certain conditions like atrial fibrillation now.

But that history underscores a crucial point.

Both fleconide and propofenone carry black box warnings for prorhythmic effects.

Meaning they can cause new or worsened dysrhythmias.

Precisely.

You're trying to fix one rhythm, but you might trigger a different, potentially more dangerous one.

Constant vigilance is needed.

Okay.

Class II, the beta blockers.

Metaprolol, Atenolol, Esmolol.

You mentioned they're cardioprotective.

Immensely so.

By blocking that sympathetic stimulation, they reduce heart rate, slow down AV node conduction, decrease myocardial oxygen demand.

All good things, especially after a heart attack.

How much do they help post -MI?

Studies show they reduce the risk of sudden cardiac death by around 25 % in that population.

That's significant.

And Esmolol is a bit different.

Right.

Esmolol is unique because it's ultra -short acting.

Given fee, its effects wear off very quickly once stopped.

This makes it useful for acute situations, like controlling rapid heart rates in supraventricular tachycardias, often in the ICU or ED, where you need tight, rapid control.

Okay.

Now for Class III, these are the drugs that prolong repolarization.

Phase III.

Amiodarone is the big name here.

It really is.

Amiodarone, Sotolol, Abutilide, Defetilide.

These are generally reserved for to treat often life -threatening ventricular tachycardias or fibrillation.

But amiodarone, well, it's in a class by itself in many ways.

Why is it so complex?

It boils down to its chemistry.

Amiodarone is extremely lipophilic.

It loves fat.

And it has an incredibly unusually long half -life.

We're talking 15 days up to maybe 100 days.

100 days is months.

Exactly.

Think about what that means.

The drug doesn't just stay in the blood.

It infiltrates and accumulates in fatty tissues throughout the entire body.

Liver, lungs, skin, eyes, everywhere.

And that systemic infiltration must be why it has such widespread side effects.

Absolutely.

The most feared is pulmonary toxicity.

It can cause irreversible pulmonary fibrosis, which can be fatal.

That's a huge concern.

What else?

Corneal microdeposits are very common tiny deposits in the cornea.

Patients often report seeing visual halos or having blurry vision.

And then there's photosensitivity.

Significant photosensitivity.

Like getting sunburn easily.

Much more than that.

With long -term use, it can actually cause a distinctive blue -gray skin discoloration, especially in sun -exposed areas.

It tells you just how deeply this drug embeds itself in the tissues.

Wow.

Okay.

Beyond those direct toxicities, what about drug interactions?

This is a critical clinical pearl you absolutely must remember.

Amiodarone significantly inhibits liver enzymes that metabolize other drugs.

Two key ones are warfarin and digoxin.

So if a patient is on warfarin and starts amiodarone, their INR will shoot up, potentially dangerously high.

Amiodarone can increase the effect of warfarin by about 50%.

You must anticipate this and proactively reduce the warfarin dose, usually by half, when starting amiodarone.

And for digoxin.

Same principle.

Amiodarone increases digoxin levels, again by about 50%.

So the digoxin dose also needs to be typically in half, to prevent toxicity.

Forgetting these adjustments can have serious consequences.

That's a vital takeaway.

What about other class 3 drugs?

You mentioned dafetylide.

Ah, dafetylide.

It's effective, but it comes with a very high risk of inducing torsades de pointe, that dangerous rhythm linked to QT prolongation.

So high.

So high that initiating dafetylide therapy requires mandatory hospitalization for a minimum of three days.

The patient needs continuous ECG monitoring during this time, specifically to watch for torsades.

Only specially trained physicians can even prescribe it.

That tells you the level of risk involved.

Or should.

Okay, let's move to class 4.

The calcium channel blockers, diltiasum and verapamil.

Right.

As we said, they block the slow calcium channels, mainly in the atria and AV node.

So their main use is for atrial issues.

Primarily.

They're great for slowing down the ventricular rate in rapid atrial fibrillation or atrial flutter.

They don't usually convert the rhythm itself, but they control the rate, which protects the ventricles.

They can also be used to terminate paroxysmal supraventricular tachycardia, PSVT.

Okay.

And lastly, that unclassified agent, adenosine.

Adenosine is unique.

It works by dramatically slowing down conduction time through the AV node.

Its main job is to convert PSVT back to a normal sinus rhythm.

And it works fast.

Incredibly fast.

Its half -life is less than 10 seconds.

Gone almost instantly.

Which means administration has to be specific.

Very specific.

It must be given as a rapid IV push, usually in a vein close to the heart, followed immediately by a saline flush to get it to the heart before it's metabolized.

And there's an expected side effect people need to be prepared for.

Yes.

Because it slams the brakes on the AV node so hard, it very commonly causes a brief period of a systole.

The heart just stops for a few seconds on the monitor.

It can be alarming to transient.

The patient might feel flushed or short of breath for a moment too.

Okay.

Wow.

That's quite an array of powerful, high alert medications.

It really underscores why the nursing process is so fundamental here.

Absolutely essential.

It starts before you even give the drug.

Assessment is key.

You need baseline vital signs, a baseline ECG, absolutely.

But crucially, you need to know the patient's liver and kidney function.

Why are they so critical?

Because impaired hepatic function, like we discussed with lidocaine or poor renal function, means the body can't metabolize or excrete these drugs properly.

The drug builds up, increasing the risk of toxicity dramatically.

This is vital for agents like lidocaine, amiodarone, procainamide, many of them.

Okay.

Then during implementation, monitoring is constant.

Non -negotiable.

You're monitoring heart rate, blood pressure continuously if possible, or very frequently.

If the pulse falls below 90 mm Hg, you generally hold the dose and notify the prescriber immediately.

And ECG monitoring.

Watching for that QT interval.

Constantly watching.

QT interval prolongation is that major warning sign for potential torsades to points.

You need to know the baseline QT and monitor for any significant lengthening.

Patient teaching must be extensive too.

Absolutely.

Safety depends on the patient understanding these drugs.

For oral doses, advise taking them with food to minimize GI upset, which is common.

And sustained release forms.

Teach them never to crush or chew sustained release tablets.

The drug is designed for slow release.

Also, reassure them if they see something that looks like a tablet shell or a wax matrix in their stool that's often normal with some formulations, the drug has been absorbed.

What about lifestyle factors?

Big ones.

Patients should avoid caffeine and alcohol.

Caffeine can worsen dysrhythmias, and alcohol can cause vasodilation and hypotension, which is risky with drugs that already lower blood pressure.

And postural hypotension.

Dizziness when standing up.

Yes, that's a risk with many of these drugs.

Teach patients to change positions,

slowly sit on the edge of the bed for a minute before standing, rise slowly from a chair.

And for amiodarone specifically.

Yeah.

That photosensitivity.

Requires serious counseling.

Strict sun avoidance is necessary.

Regular sunscreen often isn't enough.

They need protective clothing, long sleeves, hats, and barrier sun blocks, the ones containing zinc oxide or titanium dioxide, especially on exposed skin.

We also need to reinforce interactions, right?

Like grapefruit juice.

Yes.

Grapefruit juice is notorious for inhibiting the metabolism of several drugs, including some anti -dysthymics like amiodarone and quinidine.

This can lead to toxic levels.

So no grapefruit juice while on these medications.

It really highlights the need for individualized care planning too.

Definitely.

And research even shows differences, for example, in atrial fibrillation.

Female patients with chronic AF tend to be older, have a higher risk of stroke from it, and their AF is often linked more with things like hypertension, obesity, or thyroid and kidney issues.

Whereas in men, it might be more commonly linked to underlying coronary artery disease.

Often, yes.

It just underscores that we can't use a one -size -fits -all approach.

We have to look at the whole patient, their comorbidities, their risk factors when planning Okay, so to wrap up this critical deep dive,

we've mapped out the heart's electrical pathways, we've used the Vaughan Williams system to classify drugs by how they target specific ion channels and action potential phases.

Right.

We've gone through the four main classes.

And crucially, we've highlighted those make or break safety checks.

Things like understanding the absolute danger of giving avilidocaine mixed with epinephrine.

Managing amiodarone's incredibly long half -life, its toxicities, and those critical warfarin and digoxin interactions.

And the need for vigilant ECG monitoring across the board, especially watching that QT interval.

So if we connect all this to the bigger picture,

think about it.

Consider the intense monitoring needed for a drug like dofetalide requiring mandatory hospitalization just to start it, or the really significant multi -organ toxicity profile of amiodarone.

Yeah, the risks are substantial.

They really are.

So what does this profound pharmacological risk, this need for constant oversight,

tell you about where dysrhythmia management might be heading?

Does it suggest that maybe we should lean more towards non -pharmacological options?

Things like cardiac ablation procedures or implantable devices like defibrillators?

Perhaps even for cases that aren't immediately life -threatening right now.

It's something for you to really mull over as you integrate all this complex pharmacology.

A really important thought to consider.

Thank you for joining us for this essential deep dive into cardiac pharmacology.